The CT26 HuSyngeneic Screen

NOW OFFERING 35% DISCOUNT per STUDY

Human Transgenic CT26 Syngeneic System
Mice were implanted with the indicated tumor cell line and then randomized into treatment groups when tumors reached ~100 mm3 (N=5 each). Tumor volume measurements (TVM) were measured by digital calipers to monitor response to treatment. Isotype control IgG was used as a negative control in this study evaluating the checkpoint inhibitors. Significant tumor regression was observed in mice treated with the checkpoint inhibitor, while control mice had progressive tumor growth.

Human Transgenic CT26 Syngeneic System

ENROLLMENT EXTENDED THROUGH February 28th!

  • Human PD1, CTLA-4 Knock-In BALB/c mice (endogenous locus)- CT26 cell line overexpressing human PD-L1 
  • Full knock-out of murine targets.
  • Endogenous expression of human targets.
  • FREE Vehicle response data (PBS only)
  • 50% off PD-1, PD-L1 or CTLA-4 treatment arms

Limited number of study animals available on first-come, first-serve basis

Reach out to us today to enroll in this screen.
Learn more about this platform here.